Linkage with cathepsin B-sensitive dipeptide promotes the in vitro and in vivo anticancer activity of PEGylated tumor necrosis factor-alpha (TNF-α) against murine fibrosarcoma

Science China Life Sciences

Volumn 54, Issue 2, 2011, Pages 128-138

  Dai, Chuan Yun ^a,b   Fu, Ya ^b   Li, Biao ^c   Wang, Yi Guang ^a   Zhang, Xuan ^a   Wang, Jian Cheng ^a   Zhang, Qiang ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b CHONGQING UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c INSTITUTE OF MEDICINAL PLANT DEVELOPMENT   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MURINAE;

EID: 79951559228     PISSN: 16747305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11427-010-4124-z     Document Type: Article

References (37)

1. Carswell E A, Old L J, Kassel R L, et al. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA, 1975, 72: 3666-3670.
2. Debs R J, Fuchs H J, Philip R, et al. Immunomodulatory and toxic effects of free and liposome-encapsulated tumor necrosis factor alpha in rats. Cancer Res, 1990, 50: 375-380.
3. Leist M, Jaattela M. Four deaths and a funeral: From caspases to alternative mechanisms. Nat Rev Mol Cell Biol, 2001, 2: 589-598.
4. Blick M, Sherwin S A, Rosenblum M, et al. Phase I study of recombinant tumor necrosis factor in cancer patients. Cancer Res, 1987, 47: 2986-2989.
5. Creaven P J, Plager J E, Dupere S, et al. Phase I clinical trial of recombinant human tumor necrosis factor. Cancer Chemoth Pharm, 1987, 20: 137-144.
6. Kimura K, Taguchi T, Urushizaki I, et al. Phase I study of recombinant human tumor necrosis factor. Cancer Chemoth Pharm, 1987, 20: 223-229.
7. Sherman M L, Spriggs D R, Arthur K A, et al. Recombinant human tumor necrosis factor administered as a five-day continuous infusion in cancer patients: phase I toxicity and effects on lipid metabolism. J Clin Oncol, 1988, 6: 344-350.
8. Chapman P B, Lester T J, Casper E S, et al. Clinical pharmacology of recombinant human tumor necrosis factor in patients with advanced cancer. J Clin Oncol, 1987, 5: 1942-1951.
9. Rosenberg S A, Lotze M T, Muul L M, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. New Engl J Med, 1987, 316: 889-897.
10. Caliceti P, Veronese F M. Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. Adv Drug Deliv Rev, 2003, 55: 1261-1277.
11. Wang Y S, Youngster S, Grace M, et al. Structural and biological characterization of PEGylated recombinant interferon alpha-2b and its therapeutic implications. Adv Drug Deliv Rev, 2002, 54: 547-570.
12. Kozlowski A, Harris J M. Improvements in protein PEGylation: PEGylated interferons for treatment of hepatitis C. J Control Release, 2001, 72: 217-224.
13. Yoshioka Y, Tsutsumi Y, Ikemizu S, et al. Optimal site-specific PEGylation of mutant TNF-α improves its antitumor potency. Biochem Bioph Res Co, 2004, 315: 808-814.
14. Yamamoto Y, Tsutsumi Y, Yoshioka Y, et al. Site-specific PEGylation of a lysine-deficient TNF-alpha with full bioactivity. Nat Biotech, 2003, 21: 546-552.
15. Wu X, Li X, Zeng Y, et al. Site-directed PEGylation of human basic fibroblast growth factor. Protein Expres Purif, 2006, 48: 24-27.
16. Otto H H, Schirmeister T. Cysteine proteases and their inhibitors. Chem Rev 1997, 97: 133-172.
17. Devetzi M, Scorilas A, Tsiambas E, et al. Cathepsin B protein levels in endometrial cancer: Potential value as a tumour biomarker. Gynecol Oncol, 2009, 112: 531-536.
18. Hashimoto Y, Kakegawa H, Narita Y, et al. Significance of cathepsin B accumulation in synovial fluid of rheumatoid arthritis. Biochem Bioph Res Co, 2001, 283: 334-339.
19. Barrett A J, Kembhavi A A, Brown M A, et al. L-trans-Epoxysuccinyl-leucylamido (4-guanidino) butane (E-64) and its analogues as inhibitors of cysteine proteases including cathepsins B, H and L. Biochem J, 1982, 201: 189-198.
20. Francisco J A, Cerveny C G, Meyer D L, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood, 2003, 102: 1458-1465.
21. Afar D E H, Bhaskar V, Ibsen E, et al. Preclinical validation of anti-TMEFF2-auristatin E-conjugated antibodies in the treatment of prostate cancer. Mol Cancer Ther, 2004, 3: 921-932.
22. Dubowchik G M, Firestone R A, Padilla L, et al. Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer activity. Bioconjug Chem, 2002, 13: 855-869.
23. Sanderson R J, Hering M A, James S F, et al. In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate. Clin Cancer Res, 2005, 11: 843-852.
24. Doronina S O, Toki B E, Torgov M Y, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotech, 2003, 21: 778-784.
25. Ajaj K A, Biniossek M L, Kratz F. Development of protein-binding bifunctional linkers for a new generation of dual-acting prodrugs. Bioconjug Chem, 2009, 20: 390-396.
26. Stocks S J, Jones A J M, Ramey C W, et al. A fluorometric assay of the degree of modification of protein primary amines with polyethylene glycol. Anal Biochem, 1986, 154: 232-234.
27. Yamazaki S, Onishi E, Enami K, et al. Proposal of standardized methods and reference for assaying recombinant human tumor necrosis factor. Jpn J Med Sci Biol, 1986, 39: 105-118.
28. Faure M P, Gaudreau P, Shaw I, et al. Synthesis of a biologically active fluorescent probe for labeling neurotensin receptors. J Biol Chem, 1994, 42: 755-763.
29. Aniento F, Roche E, Cuervo A M, et al. Uptake and degradation of glyceraldehyde-3-phosphate dehydrogenase by rat liver lysosomes. J Biol Chem, 1993, 268: 10463-10470.
30. Murata M, Miyashita S, Yokoo C, et al. Novel epoxysuccinyl peptides. Selective inhibitors of cathepsin B, in vitro. FEBS Lett, 1991, 280: 307-310.
31. Barrett A J, Kirschke H. Cathepsin B, Cathepsin H, and Cathepsin L. Methods Enzymol, 1981, 80: 535-561.
32. Tsutsumi Y, Kihira T, Tsunoda S, et al. Molecular design of hybrid tumor necrosis factor-alpha III: Polyethylene glycol-modified tumor necrosis factor-alpha has markedly enhanced antitumor potency due to longer plasma half-life and higher tumor accumulation. J Pharmacol Exp Ther, 1996, 278: 1006-1011.
33. Satoh T, Hosokawa M. The mammalian carboxylesterases: From molecules to functions. Annu Rev Pharmacol Toxicol, 1998, 38: 257-288.
34. Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen consumption and tissue oxygenation of human tumors. Adv Exp Med Biol, 1990, 277: 895-905.
35. Mahajan S S, Hou L, Doneanu C, et al. Optimization of bivalent glutathione S-transferase inhibitors by combinatorial linker design. J Am Chem Soc, 2006, 128, 8615-8625.
36. Vasey P A, Kaye S B, Morrison R, et al. Phase I clinical and pharmacokinetic study of PK1 (HPMA copolymer doxorubicin): First member of a new class of chemotherapeutic agents-drug-polymer conjugates. Clin Cancer Res, 1999, 5: 83-94.
37. Yokoyama M, Okano T, Sakurai Y, et al. Toxicity and antitumor activity against solid tumors of micelle-forming polymeric anticancer drug and its extremely long circulation in blood. Cancer Res, 1991, 51: 3229-3236.